Shares of 20/20 Biolabs, Inc. ( AIDX ) are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare.

20/20 Biolabs ( AIDX ) stock is testing lower boundaries. What’s pressuring AIDX?

Kidney Disease Algorithm To Be Integrated Into Biolabs’s Longevity Platform

20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools. According to the agreement, Rokit will reimburse 20/20 Biolabs ( AIDX ) for one-third of expenses in exchange for a running royalty on net sales of the combined product.

The companies may also negotiate a separate agreement under which ROKIT may receive exclusive rights to commercialize 20/20’s longevity platform in Korea and potentially other East Asian markets.

“This agreement is a strong validation of our platform strategy. We believe that combining advanced biomarker tracking with evidence based nutritional support will help improve therapeutic outcomes across multiple chronic disease areas,” said Jonathan Cohen, president and CEO of 20/20 Biolabs ( AIDX ).

AIDX Shares Sinks Below Key Averages

AIDX is trading 46.1% below its 20-day simple moving average (SMA) of $3.15, reinforcing that the near-term trend is still pointed down, and shares are down 92.87% over the past 12 months. The stock is also sitting much closer to its 52-week low than its 52-week high, with Tuesday marking a fresh 52-week low.

The RSI is at 3.17, which is deeply oversold and often signals capitulation-style selling rather than a "normal" pullback. MACD data is not available here, so traders are leaning heavily on price structure and mean-reversion signals like RSI to gauge whether selling pressure is exhausting.

AIDX Price Action: 20/20 shares are trading down 14.57% at $1.70 at the time of publication on Tuesday, according to Benzinga Pro.

Image: Shutterstock